Oropharyngeal Neoplasms clinical trials
The registry lists 369 studies for Oropharyngeal Neoplasms across more than 10 countries. 103 are recruiting or about to start. 180 of them are mainly about Oropharyngeal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.
Get an email when these change. Save the Oropharyngeal Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (28) · M.D. Anderson Cancer Center (26) · Mayo Clinic (11) · Memorial Sloan Kettering Cancer Center (10) · Rigshospitalet, Denmark (8) · UNC Lineberger Comprehensive Cancer Center (8) · Emory University (6) · Abramson Cancer Center at Penn Medicine (5)
What is being tested here
Drugs under test in Oropharyngeal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cisplatin | 9 | 6 | 26 |
| Carboplatin | 4 | 2 | 11 |
| Paclitaxel | 2 | 0 | 9 |
| Docetaxel | 2 | 2 | 5 |
| Prednisone | 2 | 0 | 2 |
| Ordastobart | 2 | 1 | 2 |
| Therapeutic Tumor Infiltrating Lymphocytes | 2 | 0 | 2 |
| Toripalimab | 2 | 0 | 2 |
| Cetuximab | 1 | 1 | 7 |
| Nivolumab | 1 | 2 | 6 |
Drug classes tested here Immune checkpoint inhibitors 6 open · Antimitotic agents 4 open · Antimetabolites 2 open · Corticosteroids 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) · Phase 3 · University of Birmingham
- Dec 2026Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia · Phase 3 · M.D. Anderson Cancer Center
- Feb 2027Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer · Phase 3 · NRG Oncology
- Oct 2027Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) · Phase 3 · Lisette Nixon
- Nov 2027Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy · Phase 3 · Jules Bordet Institute
- Nov 2026Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Ryan Carey
- Nov 2026Transoral and Cervical Ultrasound of Patients With Suspected Oropharyngeal Cancer · Tobias Todsen
- Dec 2026Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) · University of Maryland, Baltimore
- Dec 2026Safety and Efficacy of APG-157 in Head and Neck Cancer · Aveta Biomics, Inc.
- Dec 2026Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma · SCG Cell Therapy Pte. Ltd.
Who these studies take
Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 7 (8%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 83 (93%) | 83 (93%) |
| 30 | 86 (97%) | 86 (97%) |
| 40 | 87 (98%) | 87 (98%) |
| 50 | 87 (98%) | 87 (98%) |
| 65 | 89 (100%) | 89 (100%) |
| 75 | 84 (94%) | 84 (94%) |
| 85 | 83 (93%) | 83 (93%) |
Across all 369 studies, recruiting or not: 9% stop at 75 or younger and 2% at 65; 4% take children; 1% are for women only and <1% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Oropharyngeal Neoplasms studies take
Of 64 phase 2 interventional studies under Oropharyngeal Neoplasms, half reached primary completion within 63 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1/2 | 45 mo33–84 · 15 studies | — | — |
| Phase 2 | 63 mo49–99 · 64 studies | — | 60 mo49–99 · 63 studies |
| Interventional, no phase | 78 mo25–153 · 54 studies | — | 78 mo27–116 · 52 studies |
| Observational | 110 mo40–… · 47 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting3
- A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)Nov 6, 2026NCT07418034
- Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)Oct 27, 2026NCT06295731
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerOct 16, 2026NCT06223568
Newly registered2
Studies
Recruiting first, then most recently updated. Showing 50 of 369. Browse all 369 → or search them.
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruitingNCT05172245Phase 12 countries
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 21 country
- A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal CancerRecruitingNCT06319963Phase 1/21 country
- Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07926906Not applicable1 country
- A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)RecruitingNCT07418034Phase 21 country
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingNCT04198766Phase 1/24 countries
- Role of Liquid Biopsies in HPV-associated Cancer Treatment MonitoringRecruitingNCT057745611 country
- PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck CancerRecruitingNCT06914999Early Phase 11 country
- Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal VolunteersRecruitingNCT009004191 country
- Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingNCT07552558Phase 1/21 country
- Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx CancerRecruitingNCT05800574Phase 21 country
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07156227Phase 11 country
- E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersRecruitingNCT05639972Phase 1/21 country
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersRecruitingNCT05686226Phase 21 country
- Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)RecruitingNCT06295731Phase 2/313 countries
- TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07898124Phase 11 country
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingNCT07195734Phase 21 country
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerRecruitingNCT06223568Phase 21 country
- Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell CarcinomaRecruitingNCT06563362Phase 21 country
- Off-line Adaptive Proton TherapyNot yet recruitingNCT078665471 country
- A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaRecruitingNCT07768189Phase 314 countries
- Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for ActionRecruitingNCT066002951 country
- Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck CancerRecruitingNCT030101501 country
- Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck CancersRecruitingNCT07857655Phase 41 country
- Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology StudiesEnrolling by invitationNCT042660931 country
- Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingNCT06997068Phase 21 country
- De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNARecruitingNCT05541016Phase 21 country
- Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the ElderlyRecruitingNCT06309225Not applicable1 country
- Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)RecruitingNCT063056761 country
- Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)Not yet recruitingNCT07832266Phase 11 country
- Multidimensional and Multimodal Profiling of Oropharyngeal CarcinomaRecruitingNCT058807971 country
- Thermotherapy for Head and Neck Cancer PatientsRecruitingNCT07690618Phase 11 country
- Adaptive RadioTherapy for OroPharynx CancerRecruitingNCT04901234Phase 22 countries
- Stereotactic Boost and Short-course Radiation Therapy for Oropharynx CancerRecruitingNCT04178174Phase 31 country
- Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerRecruitingNCT06532279Phase 21 country
- Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal CarcinomaRecruitingNCT06254911Phase 21 country
- Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT StudyRecruitingNCT04900623Phase 21 country
- Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal CancerRecruitingNCT06445114Phase 21 country
- The Minimalist Trial-2RecruitingNCT06702033Phase 21 country
- HPV-associated Oropharyngeal Carcinoma (HPV-OPC)RecruitingNCT07718620Not applicable1 country
- SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal CancerNot yet recruitingNCT07241273Not applicable1 country
- Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx CancerRecruitingNCT05388773Phase 21 country
- Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or RadiationRecruitingNCT06662058Not applicable1 country
- pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerRecruitingNCT05799144Phase 21 country
- Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"RecruitingNCT01365169Not applicable1 country
- Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT TrialRecruitingNCT07178301Phase 21 country
- SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal CancerRecruitingNCT05451004Phase 32 countries
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer SurvivorsRecruitingNCT04151082Phase 1/21 country
- Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical InterventionRecruitingNCT068212431 country